bioRxiv · 10.1101/772137
Computationally Guided Design of Dipeptidyl Peptidase-4 Inhibitors
Abstract
The Type 2 Diabetes Mellitus (T2DM) epidemic undoubtedly creates a need for the development of new pharmaceuticals. With the goal of generating new therapeutics for this disease, computational studies were conducted to design novel dipeptidyl peptidase-4 (DPP-4) inhibitors. Two candidates, generated by chemical intuition-driven design and bioisosteric replacement, were found to have better docking scores than anagliptin, a currently available diabetes medication.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Reynolds, L. C., Connolly, M. P., Siegel, J. B.. 2019-09-18. Computationally Guided Design of Dipeptidyl Peptidase-4 Inhibitors. https://doi.org/10.1101/772137
Cite the original work for its findings. Save a collection to share your selection of sources.